The World's First Integrated Development & Manufacturing Organization (IDMO)

Overcome the Limitations of Conventional CDMOs

CELLARES

Join the IDMO Revolution to Unlock the Full Potential of Your Cell Therapy

Partnering with Cellares offers a fast and low-risk opportunity to automate and transfer your process onto the Cell Shuttle

Partner's Cell Therapy Process

6 months

Assess

- Partner shares process information with Cellares
- Cellares establishes process automation plan
- Cellares provides process-specific per batch price

Transfer

- Transfer & automate critical unit operations
- Analytical transfer as required to support automation

Automate

- Fully automated end-to-end run of the Partner's process
- Achieve partner defined success criteria

Contact bd@cellares.com for more information

CELLARES

Overcoming Conventional CDMO Limitations through *Vertical Integration*



CELL SHUTTLE ™

Compact automation enables concurrent processing of up to 16 batches and 90% reduction in labor and facility size

Consumable Cartridge

Closing and automating the process reduces process failure rates by 75% compared to open and manual methods

Software

Powerful and flexible software supports 90% of allogeneic and autologous cell therapy modalities

ADVANCED TECHNOLOGIES

VERTICAL INTEGRATION

MANUFACTURING SERVICES

South San Francisco (CA)

Preclinical & Clinical Services / Technology Development

- 57,000 ft²
- cGMP-ready in H1/2024
- 2 Cell Shuttles (capacity)
- 1,600 patient doses per year (based on a 7 day process)

Bridgewater (NJ)

Preclinical, Clinical & Commercial Services

- 118,000 ft²
- cGMP-ready in H2/2024
- 50 Cell Shuttles (capacity)
- 40,000 patient doses per year (based on a 7 day process)

CELLARES

IDMO Services & Capabilities

Our fully integrated services offering includes:

- Technology Adoption Program (TAP)
- Cell Therapy Process Development (PD)
- Cell Therapy Analytical Development (AD)
- Clinical & Commercial GMP Manufacturing
- Quality Assurance/Quality Control Services
- Regulatory Support

IDMO Advantage

IDMO Smart Factories leverage fully integrated technologies to produce 10 times more cell therapy batches per year than conventional CDMO facilities, with the same footprint and the same workforce

- **Capacity** - Global network of IDMO Smart Factories will meet total patient demand
- **Cost Savings** - 50% lower price per batch compared with conventional CDMOs
- **Quality** - 75% lower process failure rates compared with open and manual methods
- **Speed** - Process automation through TAP within 6 months
- **Flexibility** - Support for 90% of cell therapy modalities (autologous & allogeneic)

Quality by Design

Our Quality by Design (QbD) approach leverages the Cell Shuttle manufacturing platform to support the development of new and innovative cell therapy drug product candidates, from pre-clinical to cGMP commercial manufacturing. This approach, combined with a thorough understanding of the fundamental biology, provides:

- Faster pathway to regulatory approval
- Integrated cGMP Quality Management System
- Experienced team of world-class regulatory and quality experts
- Comprehensive regulatory pathway to ensure global compliance

CELLARES